Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study.

van den Bent, M; Baumert, B; Erridge, S; Vogelbaum, M; Nowak, A; Sanson, M; Brandes, A; Clement, P; Baurain, J; Mason, W; Wheeler, H; Chinot, O; Gill, S; Griffin, M; Brachman, D; Taal, W; Rudà, R; Weller, M; McBain, Catherine A; Reijneveld, J; Enting, R; Weber, D; Lesimple, T; Clenton, S; Gijtenbeek, A; Pascoe, S; Herrlinger, U; Hau, P; Dhermain, F; van Heuvel, I; Stupp, R; Aldape, K; Jenkins, R; Dubbink, H; Dinjens, W; Wesseling, P; Nuyens, S; Golfinopoulos, V; Gorlia, T; Wick, W; Kros, J

Affiliation

Neuro-Oncology Unit, Brain Tumour Centre at Erasmus MC Cancer Institute, Rotterdam, Netherlands

Issue Date

2017-08-08

Metadata

Show full item record

Abstract

The role of temozolomide chemotherapy in newly diagnosed 1p/19q non-co-deleted anaplastic gliomas, which are associated with lower sensitivity to chemotherapy and worse prognosis than 1p/19q co-deleted tumours, is unclear. We assessed the use of radiotherapy with concurrent and adjuvant temozolomide in adults with non-co-deleted anaplastic gliomas.

Citation

Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. 2017 Lancet

Journal

Lancet

URI

http://hdl.handle.net/10541/620551

DOI

10.1016/S0140-6736(17)31442-3

PubMed ID

28801186

Type

Article

Language

ISSN

1474-547X

Collections

All Christie Publications